[ad_1]
LOS ANGELES, June 16, 2022 /PRNewswire/ — Nonagen Bioscience, a cancer diagnostics company, today announced CE marking for its Oncuria® immunoassay for bladder cancer.
Oncuria is the first-of-its-kind multiplex urine test for the quantitative detection of 10 biomarkers in urine that are associated with the presence of bladder cancer. Bladder cancer is the tenth most diagnosed cancer in the world, with approximately 573,000 newly diagnosed cases worldwide each year.1 Bladder cancer is also highly recurrent. In fact, up to 77% of early-stage bladder tumors treated with current approaches (tumor resection and/or intravesical bacillus Calmette-Guérin [BCG] or chemotherapy) will recur.2
Oncuria now bears the CE marking and is registered under the EU In Vitro Diagnostic Directive …
Full story available on Benzinga.com
[ad_2]
Source link
